Journal of Clinical Oncology, Vol 10, 772-778, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine

HM Kantarjian, MJ Keating, EH Estey, S O'Brien, S Pierce, M Beran, C Koller, E Feldman and M Talpaz
Department of Hematology, M.D. Anderson Cancer Center, Houston, TX 77030.

PURPOSE: To evaluate the efficacy of interferon-alpha (IFN-A) and low- dose cytarabine (ara-C) combination chemotherapy in patients with chronic myelogenous leukemia (CML). PATIENTS AND METHODS: Sixty patients with advanced phases of Philadelphia chromosome (Ph)-positive CML received combination therapy with IFN-A 5 x 10(6) U/m2 daily, and low-dose ara-C 15 mg/m2 daily for 2 weeks every 4 weeks until remission, then for 1 week every month as maintenance. Forty patients were in late chronic-phase CML, and 20 were in accelerated-phase CML (16 with clonal evolution only, four with other criteria). Their outcome was compared with 58 patients (39 late chronic-phase CML and 19 accelerated-phase CML) who had been previously treated with IFN-A alone in the same dose schedule. RESULTS: In late chronic-phase CML, patients receiving IFN-A plus ara-C had a better complete hematologic response (CHR) rate compared with those treated with IFN-A alone (55% v 28%; P = .02), a trend for better Ph suppression (15% v 5%; P = .13), and a longer survival (3-year survival rate 75% v 48%; P less than .01). These differences do not seem to be caused by imbalances in prognostic factors between the two treatment groups. In accelerated-phase CML, the addition of ara-C to IFN-A did not improve the response rate of treated patients, and the difference in survival was accounted for by different patient characteristics. Suppression of clonal evolution was observed in five patients (25%). Patients with clonal evolution as the only criterion for disease acceleration had a longer survival than those with other or additional accelerated-phase criteria (3-year survival rate 67% v 22%; P less than .01). CONCLUSION: The results with the combination of IFN-A plus ara-C in late chronic-phase CML are encouraging, and suggest the need for its evaluation in early chronic- phase CML.

This article has been cited by other articles:

				K. M. Diehl, E. T. Keller, and K. M. Woods Ignatoski Why should we still care about oncogenes? Mol. Cancer Ther., February 1, 2007; 6(2): 418 - 427. [Abstract] [Full Text] [PDF]

				T. J. Kemp, J. M. Moore, and T. S. Griffith Human B Cells Express Functional TRAIL/Apo-2 Ligand after CpG-Containing Oligodeoxynucleotide Stimulation J. Immunol., July 15, 2004; 173(2): 892 - 899. [Abstract] [Full Text] [PDF]

				M. W. N. Deininger and B. J. Druker Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib Pharmacol. Rev., September 1, 2003; 55(3): 401 - 423. [Abstract] [Full Text] [PDF]

				M. E. O'Dwyer, M. J. Mauro, G. Kurilik, M. Mori, S. Balleisen, S. Olson, E. Magenis, R. Capdeville, and B. J. Druker The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML Blood, August 13, 2002; 100(5): 1628 - 1633. [Abstract] [Full Text] [PDF]

				H. M. Kantarjian, S. O'Brien, J. E. Cortes, T. L. Smith, M. B. Rios, J. Shan, Y. Yang, F. J. Giles, D. A. Thomas, S. Faderl, et al. Treatment of Philadelphia Chromosome-positive, Accelerated-phase Chronic Myelogenous Leukemia with Imatinib Mesylate Clin. Cancer Res., July 1, 2002; 8(7): 2167 - 2176. [Abstract] [Full Text] [PDF]

				H. M. Kantarjian, M. Talpaz, S. O'Brien, T. L. Smith, F. J. Giles, S. Faderl, D. A. Thomas, G. Garcia-Manero, J.-P. J. Issa, M. Andreeff, et al. Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-{alpha}: Follow-Up Results Clin. Cancer Res., July 1, 2002; 8(7): 2177 - 2187. [Abstract] [Full Text] [PDF]

				M. Talpaz, R. T. Silver, B. J. Druker, J. M. Goldman, C. Gambacorti-Passerini, F. Guilhot, C. A. Schiffer, T. Fischer, M. W. N. Deininger, A. L. Lennard, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood, March 15, 2002; 99(6): 1928 - 1937. [Abstract] [Full Text] [PDF]

				M. Baccarani, G. Rosti, A. de Vivo, F. Bonifazi, D. Russo, G. Martinelli, N. Testoni, M. Amabile, M. Fiacchini, E. Montefusco, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia Blood, March 1, 2002; 99(5): 1527 - 1535. [Abstract] [Full Text] [PDF]

				M. Talpaz, S. O'Brien, E. Rose, S. Gupta, J. Shan, J. Cortes, F. J. Giles, S. Faderl, and H. M. Kantarjian Phase 1 study of polyethylene glycol formulation of interferon {alpha}-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia Blood, September 15, 2001; 98(6): 1708 - 1713. [Abstract] [Full Text] [PDF]

				E. Jonasch and F. G. Haluska Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities Oncologist, February 1, 2001; 6(1): 34 - 55. [Abstract] [Full Text]

				B. J. Druker, C. L. Sawyers, R. Capdeville, J. M. Ford, M. Baccarani, and J. M. Goldman Chronic Myelogenous Leukemia Hematology, January 1, 2001; 2001(1): 87 - 112. [Abstract] [Full Text] [PDF]

				H. M. Kantarjian, M. Talpaz, T. L. Smith, J. Cortes, F. J. Giles, M. B. Rios, S. Mallard, J. Gajewski, A. Murgo, B. Cheson, et al. Homoharringtonine and Low-Dose Cytarabine in the Management of Late Chronic-Phase Chronic Myelogenous Leukemia J. Clin. Oncol., October 20, 2000; 18(20): 3513 - 3521. [Abstract] [Full Text] [PDF]

				H. Kantarjian, J. V. Melo, S. Tura, S. Giralt, and M. Talpaz Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies Hematology, January 1, 2000; 2000(1): 90 - 109. [Abstract] [Full Text] [PDF]

				R. T. Silver, S. H. Woolf, R. Hehlmann, F. R. Appelbaum, J. Anderson, C. Bennett, J. M. Goldman, F. Guilhot, H. M. Kantarjian, A. E. Lichtin, et al. An Evidence-Based Analysis of the Effect of Busulfan, Hydroxyurea, Interferon, and Allogeneic Bone Marrow Transplantation in Treating the Chronic Phase of Chronic Myeloid Leukemia: Developed for the American Society of Hematology Blood, September 1, 1999; 94(5): 1517 - 1536. [Abstract] [Full Text] [PDF]

				S. Faderl, M. Talpaz, Z. Estrov, and H. M. Kantarjian Chronic Myelogenous Leukemia: Biology and Therapy Ann Intern Med, August 3, 1999; 131(3): 207 - 219. [Abstract] [Full Text] [PDF]

				H. M. Kantarjian, S. O'Brien, T. L. Smith, M. B. Rios, J. Cortes, M. Beran, C. Koller, F. J. Giles, M. Andreeff, S. Kornblau, et al. Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Chronic Myelogenous Leukemia With Daily Doses of Interferon Alpha and Low-Dose Cytarabine J. Clin. Oncol., January 1, 1999; 17(1): 284 - 284. [Abstract] [Full Text] [PDF]

				F. Guilhot, C. Chastang, M. Michallet, A. Guerci, J.-L. Harousseau, F. Maloisel, R. Bouabdallah, D. Guyotat, N. Cheron, F. Nicolini, et al. Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia N. Engl. J. Med., July 24, 1997; 337(4): 223 - 229. [Abstract] [Full Text] [PDF]